Director James Tananbaum Invests $2.52M in Latigo Biotherapeutics at the IPO Price
LTGO is trading near its 52-week low of $17.22 (7.8% above the low).
Summary
Director and 10% owner James B. Tananbaum bought $2.52 million of Latigo Biotherapeutics stock at the $18.00 IPO price on the first day of trading, a strong vote of confidence from a major insider.
Key Events · Ownership and Investor Activity · LTGO
-
Director Buys $2.52M at IPO Price
James B. Tananbaum, a director and 10% owner, purchased 140,000 shares at $18.00 for a total of $2.52 million on the IPO date, August 10, 2026.
-
Preferred Stock Converts to Common
Upon the IPO closing, 9,041,328 shares of preferred stock and a convertible note automatically converted into common stock, increasing Tananbaum's indirect holdings to 18,222,656 shares across affiliated funds.
-
Insider Aligns with Public Investors
The open-market purchase at the IPO price demonstrates alignment with new public shareholders and confidence in the company's valuation.
Analysis · LTGO · Life Sciences
On the day Latigo Biotherapeutics went public at $18.00 per share, director and 10% owner James B. Tananbaum purchased 140,000 shares for $2.52 million in the open market. This is a real-money commitment at the IPO price, not a derivative conversion or grant. The purchase is significant for a director, signaling conviction in the company's valuation at the offering. Separately, Tananbaum's affiliated funds converted 9.04 million preferred shares and a convertible note into common stock upon the IPO closing, resulting in indirect ownership of 18.2 million shares. The conversion is mechanical and expected, but the open-market buy stands out as a bullish signal from a key insider.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTGO was trading at $18.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $17.22 to $19.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.